Cited by 41Wound Healing and TreatmentsStatistical Methods in Clinical TrialsDiabetic Foot Ulcer Assessment and Management

The FDA and designing clinical trials for chronic cutaneous ulcers

Maderal, Andrea D., Vivas, Alejandra C., Eaglstein, William H., Kirsner, Robert S.·2012·Seminars in Cell & Developmental Biology

Abstract

Treatment of chronic wounds can present a challenge, with many patients remaining refractory to available advanced therapies. As such, there is a strong need for the development of new products. Unfortunately, despite this demand, few new wound-related drugs have been approved over the past decade. This is in part due to unsuccessful clinical trials and subsequent lack of Food and Drug Administration (FDA) approval. In this article, we discuss the FDA approval process, how it relates to chronic wound trials, common issues that arise, and how best to manage them. Additionally, problems encountered specific to diabetic foot ulcers (DFU) and venous leg ulcers (VLU) are addressed. Careful construction of a clinical trial is necessary in order to achieve the best possible efficacy outcomes and thereby, gain FDA approval. How to design an optimal trial is outlined.

Integrity signals

Registry

Crossref · 10.1016/j.semcdb.2012.09.014

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 34 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Maderal, A. D., Vivas, A. C., Eaglstein, W. H., & Kirsner, R. S.
Affiliations
University of Miami (US)
Corresponding author
Kirsner, Robert S.
Venue
Seminars in Cell & Developmental Biology
Publisher
Elsevier BV
Published
2012-12
Volume
23
Issue
9
Pages
993-999
ISSN
1084-9521 (ISSN-L)
OpenAlex
W2047254124
Cited by
41
References
34
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 1 · 2022: 9 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 4 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 1
FWCI
0.24
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Cell and Developmental Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rehabilitation › Wound Healing and Treatments
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
Keywords
chronic wounds, chronic cutaneous ulcers, clinical trial design, FDA drug approval, diabetic foot ulcer, venous leg ulcers, drug development
MeSH terms
Chronic Disease, Clinical Trials as Topic, Humans, Research Design, Skin Ulcer, United States, United States Food and Drug Administration, Varicose Ulcer, Wound Healing, Drugs, Investigational, Treatment Outcome, Drug Approval, Diabetic Foot, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review